发明名称 |
Transfer hydrogenation of cyclopamine analogs |
摘要 |
Provided herein is a process for the transfer-hydrogenation of ketone analogs of members of the jervine type of Veratrum alkaloids, such as cyclopamine. Also provided herein are novel ruthenium transfer-hydrogenation catalysts. |
申请公布号 |
US9376447(B2) |
申请公布日期 |
2016.06.28 |
申请号 |
US201113232898 |
申请日期 |
2011.09.14 |
申请人 |
Infinity Pharmaceuticals, Inc. |
发明人 |
Genov Daniel G.;Austad Brian C.;White Brian H. |
分类号 |
C07D491/048;C07F17/02 |
主分类号 |
C07D491/048 |
代理机构 |
McDermott Will & Emery LLP |
代理人 |
Evans Susan T.;McDermott Will & Emery LLP |
主权项 |
1. A process for preparing a compound of formula (II-a): or a pharmaceutically acceptable form thereof; from a compound of formula (I-a): or a pharmaceutically acceptable form thereof; wherein:
R1 is H or a nitrogen protecting group;the process comprising reacting a compound of formula (I-a) or a pharmaceutically acceptable form thereof with a chiral ruthenium transfer-hydrogenation catalyst of formula RuClAr(chiral amino alcohol) or RuHClAr(chiral amino alcohol), wherein Ar represents a substituted benzene ligand selected from mesitylene, cymene and hexamethylbenzene and chiral amino alcohol represents a chiral amino alcohol bidentate ligand selected from ephedrine, pseudoephedrine, 2-methylaminocyclohexanol, propranolol, 1-amino-2-indanol, and prolinol, in the presence of an organic alcohol hydrogen donor selected from the group consisting of methanol, ethanol, isopropanol, and t-butanol under conditions effective to provide a substantially enantiomerically pure compound of formula (II-a) or a pharmaceutically acceptable form thereof in at least about 85% weight percent relative to an enantiomer having an (R)-stereochemical orientation at the ring carbon atom that is directly attached to the hydroxyl group. |
地址 |
Cambridge MA US |